Central Pathology Review Committee

In the PROTECTOR study, tissue and cell samples taken during RRESDO and RRSO surgery are first examined by local hospital pathology teams and then independently reviewed by a specialist from the Central Pathology Review Committee. This extra review, which is unique to PROTECTOR, helps ensure that early ovarian and fallopian tube cancers and pre-cancerous changes are identified as accurately and consistently as possible.

 

Professor Glenn McCluggage is a Consultant Histopathologist at Royal Group of Hospitals Trust, Belfast, and an Honorary Professor in Gynaecological Pathology at Queen’s University of Belfast. He has published more than 720 papers in peer-reviewed journals, including original publications and many invited editorials and reviews. He is on the Editorial Board of several major pathology journals (Modern Pathology, Human Pathology, Advances in Anatomic Pathology, International Journal of Gynecological Pathology, Virchows Archives), a member of the International Advisory Board of Journal of Clinical Pathology, and associate editor of Histopathology. He is a past President of the International Society of Gynaecological Pathologists and was previously secretary of this society. Previously he was President of the British Association of Gynaecological Pathologists. He has an extremely busy referral practice and receives numerous consultation cases from all over the world. He has been invited to lecture at numerous national and international meetings. He has authored or co-authored the various Royal College of Pathologists datasets in the United Kingdom on reporting gynaecological malignancies and has chaired the ICCR (International Collaboration on Cancer Reporting) panels developing international guidelines for reporting endometrial, ovarian, and cervical carcinomas. He is also the ICCR series champion for gynaecological neoplasms. He has been part of the last four WHO groups formulating the classification of Tumours of the Female Genital Tract, and is one of the editors on the recently published 2026 WHO Classification. 

 

 

Dr Rupali Arora currently works as Lead Gynae-oncology Pathologist at University College London Hospitals NHS Foundation Trust. She has been actively involved in collaborative research in gynae-oncology since 2007. Her research interest is in gynae-oncology, specifically identifying biomarkers for early detection and prognostication of gynaecological cancers. Apart from her diagnostic work, she has helped to validate new immunohistochemical diagnostic and prognostic markers. During her sabbatical in the USA, she worked for nine months at the University of Southern California in the molecular pathology laboratory, trying to better understand the molecular pathways for various gynaecological cancers. Dr Arora has been the lead UCLH pathologist for a number of national and international trials, and has published in many journals including Nature Communications, Oncology, International Journal of Gynaecological Cancer, International Journal of Gynaecological Pathology and American Journal of Surgical Pathology."